S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NYSE:ALVO

Alvotech (ALVO) Stock Price, News & Analysis

$12.22
-0.46 (-3.63%)
(As of 03/28/2024 ET)
Today's Range
$12.20
$12.92
50-Day Range
$12.22
$17.27
52-Week Range
$6.70
$18.00
Volume
88,283 shs
Average Volume
201,132 shs
Market Capitalization
$381.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.67

Alvotech MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
3.7% Upside
$12.67 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.27mentions of Alvotech in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.79) to ($0.23) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.14 out of 5 stars

ALVO stock logo

About Alvotech Stock (NYSE:ALVO)

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

ALVO Stock Price History

ALVO Stock News Headlines

Alvotech (NYSE:ALVO) PT Raised to $20.00
Alvotech (ALVO) Q4 2023 Earnings Call Transcript
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Contrasting Alvotech (ALVO) & Its Peers
Alvotech Announces Increase in Number of Own Shares
Alvotech Announces Increase in Number of Own Shares
Q4 2023 Alvotech SA Earnings Call
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
TEVA Mar 2024 10.000 call
TEVA Mar 2024 15.500 put
Alvotech appoints new interim Chief Quality Officer
TEVA Mar 2024 14.500 put
Alvotech Appoints Interim Chief Quality Officer
Alvotech Appoints Interim Chief Quality Officer
TEVA Jun 2024 14.000 put
TEVA Stock Pops 4% as Teva Receives FDA Approval
See More Headlines
Receive ALVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alvotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/29/2024
Next Earnings (Estimated)
5/17/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Fax
N/A
Employees
917
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.67
High Stock Price Target
$20.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+3.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-551,730,000.00
Net Margins
-967.97%
Pretax Margin
-712.04%

Debt

Sales & Book Value

Annual Sales
$93.38 million

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.12
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Robert Wessman (Age 54)
    CEO, Founder & Executive Chairman
  • Mr. Joel Morales (Age 46)
    Chief Financial Officer
  • Mr. Faysal Kalmoua (Age 48)
    COO & Director
  • Mr. Giedrius Zunda
    Chief Technical Officer
  • Mr. Joseph E. McClellan (Age 50)
    Chief Scientific Officer
  • Ms. Tanya Zharov (Age 57)
    General Counsel
  • Mr. Anil Okay (Age 38)
    Chief Commercial Officer
  • Mr. Ming Li (Age 47)
    Chief Strategy Officer
  • Ms. Christina Siniscalchi
    Interim Chief Quality Officer

ALVO Stock Analysis - Frequently Asked Questions

Should I buy or sell Alvotech stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alvotech in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALVO shares.
View ALVO analyst ratings
or view top-rated stocks.

What is Alvotech's stock price target for 2024?

2 brokerages have issued 1-year price targets for Alvotech's stock. Their ALVO share price targets range from $8.00 to $20.00. On average, they anticipate the company's share price to reach $12.67 in the next twelve months. This suggests a possible upside of 3.7% from the stock's current price.
View analysts price targets for ALVO
or view top-rated stocks among Wall Street analysts.

How have ALVO shares performed in 2024?

Alvotech's stock was trading at $11.48 at the beginning of the year. Since then, ALVO stock has increased by 6.4% and is now trading at $12.22.
View the best growth stocks for 2024 here
.

When is Alvotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 17th 2024.
View our ALVO earnings forecast
.

Who are Alvotech's major shareholders?

Alvotech's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Oaktree Capital Management LP (0.00%), Vanguard Group Inc. (0.00%), Vanguard Group Inc. (9.80%), Oaktree Fund Advisors LLC (0.00%), Citadel Advisors LLC (0.05%) and Wolverine Asset Management LLC (0.00%).

How do I buy shares of Alvotech?

Shares of ALVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ALVO) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners